A sponsor developing a first-in-class therapy for sickle cell disease (SCD) needed to rapidly generate safety, pharmacokinetic (PK), and early efficacy data to support continued clinical development. The study represented a critical opportunity, as no disease-modifying treatments were widely available at the time, and early signals of efficacy could significantly influence regulatory and development strategy.